Fred Mermelstein, president and founder, said: “Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain. It will be well-suited for both civilian and military use in medically supervised settings.”
David Bernstein, Javelin’s general counsel and chief intellectual property counsel said: “They are very excited to have this important pharmaceutical composition patent issue, this patent broadens their overall intellectual property portfolio and adds further strength specifically in ketamine. At the same time, it significantly extends the term of commercial exclusivity for Javelin’s intranasal ketamine products.”